(PDF) Php359 - Impact of Expedited Marketing Authorisation

Php359 - Impact of Expedited Marketing Authorisation on Pricing and Reimbursement Outcomes for Drugs in the Us and Eu-5

Value in Health - United Kingdom

doi 10.1016/j.jval.2018.09.1253

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

October 1, 2018

Authors

M.A. Izmirlieva

Publisher

Elsevier BV

Related search

Pricing and Reimbursement of Orphan Drugs: The Need for More Transparency

Orphanet Journal of Rare Diseases

English

Pcp37 - The Confidentiality Regarding Drugs Pricing and Reimbursement in Romania

Value in Health

Occupational Health

English

Php140 - Current Challenges and Potential Solution for Pricing Regulatory and Reimbursement Framework of Innovative Drugs in Egypt

Value in Health

Occupational Health

English

Impact of Amending the Acetylcysteine Marketing Authorisation on Treatment of Paracetamol Overdose

ISRN Toxicology

English

Flexible and Expedited Regulatory Review Processes for Innovative Medicines and Regenerative Medical Products in the US, the EU, and Japan

International Journal of Molecular Sciences

Organic Chemistry

Molecular Biology

Theoretical Chemistry

Inorganic Chemistry

Computer Science Applications

English

Price Comparison of New Drugs in Japan, Eu and Us

Value in Health

Occupational Health

English

EU and US Cybersecurity Strategies and Their Impact on Businesses and Consumers

Computer Science

English

Manufacturing Process Development of ATMPs Within a Regulatory Framework for EU Clinical Trial & Marketing Authorisation Applications

Cell and Gene Therapy Insights

English

PCN177 Assessment of Reimbursement Processes and Outcomes for Cancer Drugs in Croatia – Comparison to NICE and NCCN Guidelines

Value in Health

Occupational Health

English